Duvet S, Labiau O, Mir A M, Kmiécik D, Krag S S, Verbert A, Cacan R
Laboratoire de Chimie Biologique, UMR no. 111 du CNRS, Université des Sciences et Technologies, 59655 Villeneuve d'Ascq Cedex, France.
Biochem J. 1998 Oct 15;335 ( Pt 2)(Pt 2):389-96. doi: 10.1042/bj3350389.
Recent studies on the mechanism of degradation of newly synthesized glycoproteins suggest the involvement of a retrotranslocation of the glycoprotein from the lumen of the rough endoplasmic reticulum into the cytosol, where a deglycosylation process takes place. In the studies reported here, we used a glycosylation mutant of Chinese hamster ovary cells that does not synthesize mannosylphosphoryldolichol and has an increased level of soluble oligomannosides originating from glycoprotein degradation. In the presence of anisomycin, an inhibitor of protein synthesis, we observed an accumulation of glucosylated oligosaccharide-lipid donors (Glc3Man5GlcNAc2-PP-Dol), which are the precursors of the soluble neutral oligosaccharide material. Inhibition of rough endoplasmic reticulum glucosidase(s) by castanospermine led to the formation of Glc3Man5GlcNAc2(OSGn2) (in which OSGn2 is an oligomannoside possessing two GlcNAc residues at its reducing end), which was then retained in the lumen of intracellular vesicles. Thus they were protected during an 8 h chase period from the action of cytosolic chitobiase, which is responsible for the conversion of OSGn2 to oligomannosides possessing one GlcNAc residue at the reducing end (OSGn1). In contrast, when protein synthesis was maintained in the presence of castanospermine, glucosylated oligomannosides (Glc1-3Man5GlcNAc1) were recovered in cytosol. Except for monoglucosylated Man5 species, which are potential substrates for luminal calnexin and calreticulin, the pattern of oligomannosides was similar to that observed on glycoproteins. The occurrence in the cytosol of glucosylated species with one GlcNAc residue at the reducing end implies that the deglycosylation process that generates glucosylated OSGn1 from glycoproteins occurs in the cytosol.
最近关于新合成糖蛋白降解机制的研究表明,糖蛋白从糙面内质网腔逆向转运至胞质溶胶参与其中,糖基化过程在胞质溶胶中发生。在本文报道的研究中,我们使用了中国仓鼠卵巢细胞的糖基化突变体,该突变体不合成甘露糖基磷酸多萜醇,且源自糖蛋白降解的可溶性低聚甘露糖水平升高。在蛋白质合成抑制剂茴香霉素存在的情况下,我们观察到了糖基化寡糖 - 脂质供体(Glc3Man5GlcNAc2 - PP - Dol)的积累,它们是可溶性中性寡糖物质的前体。粟精胺对糙面内质网葡萄糖苷酶的抑制导致了Glc3Man5GlcNAc2(OSGn2)的形成(其中OSGn2是一种在其还原端具有两个GlcNAc残基的低聚甘露糖),然后它被保留在细胞内囊泡腔中。因此,在8小时的追踪期内,它们受到胞质壳二糖酶作用的保护,胞质壳二糖酶负责将OSGn2转化为在还原端具有一个GlcNAc残基的低聚甘露糖(OSGn1)。相反,当在粟精胺存在的情况下维持蛋白质合成时,糖基化低聚甘露糖(Glc1 - 3Man5GlcNAc1)在胞质溶胶中被回收。除了单糖基化的Man5物种(它们是腔内钙连接蛋白和钙网蛋白的潜在底物)外,低聚甘露糖的模式与在糖蛋白上观察到的相似。在胞质溶胶中出现还原端带有一个GlcNAc残基的糖基化物种意味着从糖蛋白产生糖基化OSGn1的去糖基化过程发生在胞质溶胶中。